Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports

BACKGROUND: Immune checkpoint inhibitor (ICI) use in clinical practice has unravelled a spectrum of immune-related adverse events (irAEs) due to immune system hyper-activation. ICI-related haemophagocytic lymphohistiocytosis (HLH) has been recently outlined in single case reports, raising a concern...

Descripción completa

Detalles Bibliográficos
Autores principales: Noseda, Roberta, Bertoli, Raffaela, Müller, Laura, Ceschi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498487/
https://www.ncbi.nlm.nih.gov/pubmed/31046841
http://dx.doi.org/10.1186/s40425-019-0598-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498487/
https://www.ncbi.nlm.nih.gov/pubmed/31046841
http://dx.doi.org/10.1186/s40425-019-0598-9

Ejemplares similares